Apr. 6, 2021—The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials
Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.
Jun. 9, 2020—After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 8, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Jan. 14, 2013—AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.